Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Dysport Therapeutic | abobotulinumtoxinA | Upper limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | ||
Ebglyss | lebrikizumab | atopic dermatitis | Active | |||
Ebixa | Memantine hydrochloride | Dementia (Alzheimer type), moderate to severe | Do not list | Complete | ||
Edarbi | Azilsartan medoxomil | Hypertension | Do not list at the submitted price | Complete | ||
Edarbyclor | Azilsartan medoxomil + chlorthalidone | Hypertension | Do not list | Complete | ||
Edurant | Rilpivirine | HIV infection | List | Complete | ||
Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | ||
Elaprase | Idursulfase | Mucopolysarccharidosis II (MPS II), Hunter Syndrome | Do not list | Complete |